Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions

 
 

 

 

An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers.

 

The investment, already underway, includes new sites, expansion at existing factories, and is additional to previously announced investments.  It follows five acquisitions made by the companies so far this year.

 

  Emmanuel Ligner , Danaher Group Executive, says: "Our customers tell us they need access to manufacturing agility, a robust global supply chain and more regional options. This investment further fuels our expansion program so we can rapidly meet the current and future needs of our customers and ultimately, their patients."

 

Cytiva and Pall Corporation's capacity expansion will increase the manufacture of key products used to make biologic medicines.

 

The companies are investing:

 
  •   600+ million USD in chromatography resins – media for analyzing or purifying biomolecules – establishing a new manufacturing site in the US.
  •  
  •   400+ million USD in cell culture media – in liquid or powder form this is used to grow and cultivate cells before they are purified– expand operations in the US, UK, and Austria .
  •  
  •   300+ million USD in single-use technologies – including bioreactor bags for growing cells used to make personalized medicines and syringe filters for scientific research – expand operations in the US and the UK, as well as fitting out a new facility in Cardiff, Wales .
  •  
  •   200+ million USD for continuing expansion work in Cytiva and Pall Corporation's sites across China and the rest of the Asia-Pacific region, Europe , and the US.
  •  

This investment also addresses some of the key challenges highlighted in the   Global Biopharma Resilience Index   , conducted by Longitude, a Financial Times company, and published by Cytiva in March 2021 . These include hiring and training talent, R&D collaboration, supply chain resilience, manufacturing models, as well as government policy and regulation.

 

   About Pall
 
  Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry.   Part of the Danaher (NYSE: DHR) family of science and technology innovators,     Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information visit     www.pall.com     .  

 

   About Cytiva
 
  Cytiva is a global life sciences leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics.   Part of the Danaher (NYSE: DHR) family of science and technology innovators, Cytiva   is a   trusted   partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. For more information visit www.cytiva.com .  

 

 Cision View original content: https://www.prnewswire.com/news-releases/cytiva-and-pall-corporation-investing-1-5-billion-usd-over-two-years-to-meet-growing-demand-for-biotechnology-solutions-301341492.html  

 

SOURCE Cytiva

 

 

 

 Cision View original content: https://www.newswire.ca/en/releases/archive/July2021/27/c1861.html  

 
 

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×